Advanced search
Publication Cover
Journal of Chemotherapy Latest Articles
Submit an article Journal homepage
135
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Meta-analysis of the efficacy and adverse effects of acalabrutinib in the management of relapsed/refractory chronic lymphocytic leukemia

Daniel Parka Department of Medicine, University of California San Francisco Medical Center-Fresno Campus, Fresno, California, USACorrespondence[email protected]
View further author information
,
Alec M. Chan-Golstonb Department of Public Health, University of California, Merced, California, USAView further author information
,
Yueqi Yanc Health Sciences Research Institute, University of California, Merced, California, USAView further author information
,
Farris Al-Manaseerd Department of Internal Medicine, Loma Linda University School of Medicine, Loma LindaCalifornia, USAView further author information
&
Mojtaba Akhtarie Department of Medicine, Division of Hematology & Oncology, Loma Linda University School of Medicine, Loma LindaCalifornia, USACorrespondence[email protected]
View further author information
Received 07 Mar 2024, Accepted 13 May 2024, Published online: 27 May 2024

References

  • Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592–601. doi: 10.1016/j.it.2013.07.002.
  • Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56–63. doi: 10.1016/j.critrevonc.2019.02.001.
  • Kriegsmann K, Kriegsmann M, Witzens-Harig M. Acalabrutinib, a second-generation bruton’s tyrosine kinase inhibitor. Recent Results Cancer Res. 2018;212:285–294. doi: 10.1007/978-3-319-91439-8_14.
  • Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363(2):240–252. doi: 10.1124/jpet.117.242909.
  • Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–332. doi: 10.1056/NEJMoa1509981.
  • Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3(9):1553–1562. doi: 10.1182/bloodadvances.2018030007.
  • Barker TH, Migliavaca CB, Stein C, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol. 2021;21(1):189. doi: 10.1186/s12874-021-01381-z.
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2.
  • Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–3452. doi: 10.1200/JCO.21.01210.
  • Furman RR, Wierda WG, Schuh A, et al. Phase 1/2 study of acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: final results with >4 years of follow-up. Blood. 2022;140(Supplement 1):9873–9875. doi: 10.1182/blood-2022-162394.
  • Ghia P, Pluta A, Wach M, et al. Acalabrutinib versus investigator’s choice in relapsed/refractory chronic lymphocytic leukemia: final ASCEND trial results. Hemasphere. 2022;6(12):e801. doi: 10.1097/HS9.0000000000000801.
  • Rogers KA, Thompson PA, Allan JN, et al. Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2021;106(9):2364–2373. doi: 10.3324/haematol.2020.272500.
  • Yazdy MS, Mato AR, Roeker LE, et al. Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: a retrospective analysis of real world patients. Blood. 2019;134(Supplement_1):4311–4311. doi: 10.1182/blood-2019-130062.
  • Sun CC, Nierman P, Ahn IE, et al. Acalabrutinib in patients with relapsed/refractory (R/R) and high-risk, treatment-naive (TN) chronic lymphocytic leukemia (CLL). Blood. 2018;132(Supplement 1):4424–4424. doi: 10.1182/blood-2018-99-110395.
  • Strati P, Keating MJ, O'Brien SM, et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014;99(8):1350–1355. doi: 10.3324/haematol.2014.104661.
  • van der Straten L, Hengeveld PJ, Kater AP, et al. Treatment approaches to chronic lymphocytic leukemia with high-risk molecular features. Front Oncol. 2021;11:780085. doi: 10.3389/fonc.2021.780085.
  • Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117(11):3016–3024. doi: 10.1182/blood-2010-08-304683.
  • Rozovski U, Keating MJ, Estrov Z. Why is the immunoglobulin heavy chain gene mutation status a prognostic indicator in chronic lymphocytic leukemia? Acta Haematol. 2018;140(1):51–54. doi: 10.1159/000491382.
  • Brown JR, Byrd JC, Ghia P, et al. Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with chronic lymphocytic leukemia (CLL). Blood. 2020;136(Supplement 1):52–54. doi: 10.1182/blood-2020-134797.
  • Nasnas P, Cerchione C, Musuraca G, et al. How I manage chronic lymphocytic leukemia. Hematol Rep. 2023;15(3):454–464. doi: 10.3390/hematolrep15030047.
  • Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901. doi: 10.1016/S0140-6736(21)00224-5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.